Our Commitment

Transforming cardiac informatics to help physicians standardize proactive management and individualized care across large patient populations

Myocardial Solutions’ (MSI) mission is to give cardiac and oncology patients control over their heart health. By quantifying subtle changes in myocardial heart function, MSI's proprietary MyoStrain® technology provides a standardized, proactive approach to help physicians effectively detect, monitor, and manage the early progression of myocardial dysfunction and prevent heart failure. Combined with its speed and efficiency, MyoStrain may provide a critical population management tool to help physicians individualize cardiac treatment for at-risk patient populations in cardiology and oncology.

With 80,000+ patient data points from over 70 medical centers in the United States and EU, MyoStrain has been rigorously validated in over 500+ publications, including 50+ in JACC and Circulation. The MyoStrain heart function test is a rapid, non-invasive MRI scan performed in under 10 minutes and has been optimized for clinical use due to its speed, ease of use, and quantitative accuracy.

We are working with hospitals and cancer centers in the United States and Europe to help transform quality of care for their patients. Together, we are pursuing a higher standard of care, focusing preventative care and personalized medicine to ultimately improve patient longevity and quality of life in cardiology and oncology.

John Funkhouser

Chairman, Chief Executive Officer
John Funkhouser has extensive experience in healthcare as CEO of four cardiac life sciences companies including CoeurLabs, PharmaNetics, nContact and now, Myocardial Solutions. Before working in healthcare, Mr. Funkhouser worked in banking and venture capital at Chemical Bank Of New York, Wheat First Securities, Crestar Capital and Hillcrest Group. He is a graduate of Princeton University and the Darden School of Business at the University of Virginia.

Nael Osman, PhD

‍Founder, Chief Science Officer
Nael Osman founded Myocardial Solutions after developing MyoStrain’s technology as a professor at Johns Hopkins University. As a known leader in cardiac MRI technology, Nael has pushed the frontiers of measuring regional function of the heart using MRI. Nael is an accomplished researcher and academician with a track record of academic publications (60+ scientific papers, 100+ conference presentations and abstracts), research contribution, teaching and life science innovation.

Rafael Rivero, MD

Chief Medical Officer, Global Head of Medical Affairs
With over 18 years of global experience leading and transforming teams across Biotech, Pharma and Medical Devices, Rafael Rivero, MD leads the initiative in expanding MyoStrain clinical utilization and advocacy within the medical community. Dr. Rivero received his MD at the Superior School of Medicine in Cuba in 1992 and his professional experience includes Monogram Biosciences, Gilead Sciences, Abbott Laboratories, Stereotaxis and Ortho Clinical Diagnostics.

Jim Whayne

Chief Clinical Officer
Jim Whayne joined Myocardial Solutions to direct clinical initiatives. He has 25 years of medical device and entrepreneurial experience, having cofounded 3 device companies – nContact, Cayenne Medical and Converge Medical. Mr. Whayne holds a Master of Science in Biomedical Engineering from the University of Virginia and a Bachelor Degree in Biomedical and Electrical Engineering from Duke University. He is also an inventor on over 200 issued US patents.

Sid Fleischman

Vice President, Engineering and Operations
Sidney Fleischman has 25 years of experience in bringing medical devices from concept to commercialization. He has cofounded several successful medical device companies, including nContact, Cayenne Medical, and Converge Medical. He holds a BS in Mechanical Engineering from UC Santa Barbara and is an inventor of more than 100 issued patents in the medical device area.

Denise McKenzie

Vice President, Finance
Denise McKenzie has extensive experience in finance and accounting with a variety of start-up companies, primarily in the healthcare industry. She has led diverse financing projects including IPOs, commercial bank financing, PIPEs, private placements, venture rounds, and acquisitions. McKenzie is a graduate of Virginia Commonwealth University with both a Bachelor’s and Master’s degree in finance with a concentration in accounting.

Transforming cardiac informatics to help physicians standardize proactive management and individualized care across large patient populations

John Funkhouser

Chairman, Chief Executive Officer

John Funkhouser has extensive experience in healthcare as Chief Executive Officer of four cardiac life sciences companies including CoeurLabs, PharmaNetics, nContact and now, MSI. Before working in healthcare, Mr. Funkhouser worked in banking and venture capital at Chemical Bank Of New York, Wheat First Securities, Crestar Capital and Hillcrest Group. He is a graduate of Princeton University and the Darden School of Business at the University of Virginia.

Dane Carl Andreeff

Dane Carl Andreeff is the current President, Chief Executive Officer and Director at Helius Medical Technologies, Inc., an advanced medical device company focused on improving neurological health and wellness. He is also the founder of Maple Leaf Partners, LLC and Andreeff Equity Advisors, LLC.

In addition to his role as Director at MSI, Andreeff is Director at HDL Therapeutics, a highly innovative medical company that has developed the first therapy of its kind to rapidly reverse coronary atherosclerosis in patients with Homozygous Familial Hypercholesterolemia (HoFH). He is also on the board at TraceSecurity, LLC, a security company helping to protect and eliminate risk for companies ranging local and community financial institutions to global enterprises.

Nelson Randy Hill

Randy Hill currently serves as a key business advisor to United Imaging in North America and specializes in consulting innovative companies across the healthcare imaging sector. Hill brings extensive experience in the medical imaging industry and a background in sales in marketing to help position MSI at the forefront of imaging innovation.

Hill has also served as Chief Executive Officer at Siemens Medical, and previously as Chief Operations Officer and VP of Service at Siemens for more than eight years. Prior to that, Hill served six years as Chief Executive Officer and Director at VasoMedical subsidiary, Vaso Diagnostics, a medical technology company ranging a diverse product and service selection, including several diagnostic imaging solutions as well as non-invasive monitoring and therapeutic devices.

Todd Ames Robinson

Todd Robinson currently serves as CEO/Principal at Southwood Group, L.L.C., with approximately $45 million in revenue and 200 employees. Robinson also serves as Managing Partner for Hanover Ventures, L.L.C., a venture partnership currently holding three primary investments, including Myocardial Solutions, Inc., VazTec, L.L.C. American Nano, L.L.C. Robinson brings in a diverse background and significant operating experience as both a manager and director.

Bob Kay

Bob Kay is currently the Managing Member and CEO of Excelleration Partners, which focuses on helping early-stage growth companies accelerate their growth while also excelling at what they do. Kay brings over 40 years of experience of broad-based banking, private equity intermediary, and private business management experience in various fields to help MSI grow commercially as a medical technology.

Kay has taken on many leadership roles in startup, growth phase and turnaround company situations. He was previously CEO and CFO of DrillingInfo, a major technology growth company, and also currently serves on the Board of MSC Income Fund, Inc.

Jeff Barber

Jeff Barber is a Managing Director with Fennebresque & Co., an investment banking firm where he focuses on technology and healthcare. Barber brings comprehensive experience to help MSI navigate the business of healthcare and medical technology.

Barber was previously in charge of PricewaterhouseCoopers technology practice in the Carolinas, served on the board of directors at PRA Health Sciences, Ply Gem Holdings, Inc., SciQuest Inc., and LipoScience, Inc. He also currently serves on the board of trustees and as chair of the audit committee of Blue Cross Blue Shield of North Carolina, on the board of directors and as past chair of Echo Health Ventures.

Gary Brock

Gary Brock brings over 40 years of progressive healthcare executive leadership and governance experience to help propel MSI forward as MyoStrain transitions to becoming a new standard in cardiac care.

Brock has served Baylor Scott & White Health for more than 35 years in numerous leadership positions, including President and Chief Operating Officer of the legacy Baylor Healthcare system, and Chief Integrated Delivery Network Officer. He created one of the largest and top-performing Accountable Care Organizations in Texas and in the nation, focusing on patient-centered care. He also served as a member of the Board of Trustees of the Texas Hospital Association, Austin, Texas and was elected chairman of the board in 2014.

Memorial MRI & Diagnostic

Memorial MRI & Diagnostic (MMD) has partnered with Myocardial Solutions to build Houston's first and only MyoStrain Cardiac Prevention Center in Katy, Texas. MMD's longstanding commitment towards improving the lives of patients through its line of state-of-the-art imaging technologies and community-focused services has made MMD the ideal caliber of outpatient imaging facilities to offer MyoStrain. With more than 10 locations spread across Greater Houston, Dallas, Beaumont, Corpus Christi and surrounding cities, the partnership will deliver the unique MyoStrain MRI heart scan to communities throughout Texas, expanding access to better cardiac care and helping patients take control of their heart health.

Learn more about MMD's unique MyoStrain offering

"We are incredibly excited to offer MyoStrain at our Katy facility, as the prevalence and risk of cardiac diseases within our community is exceedingly high. In addition to providing a uniquely accurate assessment of heart health, MyoStrain also gives us the speed and efficiency to address large at-risk patient populations. We believe it is a vital solution to help our community’s care providers proactively manage heart health while supporting the enormous volume of patients in need of cardiac care.”
Kim Tran
Chief Executive Officer at Memorial MRI & Diagnostic

United Imaging Healthcare Solutions

United Imaging, a global leader in advanced medical imaging and radiotherapy equipment, has partnered with Myocardial Solutions Inc. to bring rapid cardiac MR imaging to unmet cancer care and cardiology markets, helping enable physicians to protect and manage patient heart health during and after cancer treatment.

United Imaging is the preferred provider for MyoStrain®, and the two companies have joined together to deliver this dedicated solution to cancer centers and hospitals. The FDA’s 510(k) pre-market clearance of MyoStrain for United Imaging MRI machines marks the availability of this novel, proprietary technology in the U.S. market.

Learn more about the uMR® 570 MyoStrain® Edition

“With this joint solution from Myocardial Solutions and United Imaging, oncologists and cardiologists will be able to monitor patient heart health before, during, and after cancer treatment. Together, United Imaging and Myocardial Solutions will deliver the diagnostic testing using MyoStrain software on a dedicated MR scanner for both cancer centers and cardiologists. The fast, MR based technique is highly automated to deliver reproducible results.”
Abram Voorhes, PhD
Vice President of MR Imaging at United Imaging

Transforming cardiac informatics to help physicians standardize proactive management and individualized care across large patient populations

Myocardial Solutions’ (MSI) mission is to give cardiac and oncology patients control over their heart health. By quantifying subtle changes in myocardial heart function, MSI's proprietary MyoStrain® technology provides a standardized, proactive approach to help physicians effectively detect, monitor, and manage the early progression of myocardial dysfunction and prevent heart failure. Combined with its speed and efficiency, MyoStrain may provide a critical population management tool to help physicians individualize cardiac treatment for at-risk patient populations in cardiology and oncology.

With 80,000+ patient data points from over 70 medical centers in the United States and EU, MyoStrain has been rigorously validated in over 500+ publications, including 50+ in JACC and Circulation. The MyoStrain heart function test is a rapid, non-invasive MRI scan performed in under 10 minutes and has been optimized for clinical use due to its speed, ease of use, and quantitative accuracy.

We are working with hospitals and cancer centers in the United States and Europe to help transform quality of care for their patients. Together, we are pursuing a higher standard of care, focusing preventative care and personalized medicine to ultimately improve patient longevity and quality of life in cardiology and oncology.